A Phase II Non-Randomized, Open-label, Multi-centre Study of the Safety and Efficacy of Tebentafusp in Melanoma with Molecular Relapsed Disease
Welcome to the TebeMRD trial website!
We are trying to find ways to improve the management of people with intermediate or high risk resected cutaneous melanoma or with primary uveal melanoma and/or who have had metastases removed by an operation.
The patient population is drawn from those completing adjuvant or local therapy for intermediate or high risk melanoma. Potential participants are approached as they enter the last 3 months of adjuvant treatment for resected cutaneous melanoma, or within 9 months of completing such treatment. In the case of uveal melanoma, entry is open to those within 3 years of completing treatment for their primary tumour or oligometastatic disease.
If you are interested in participating in the TebeMRD Trial a list of our participating hospitals can be found on the Recruiting Sites tab.
Details on participating in the trial are provided in our Patient Information Sheets.
If you would like more information regarding the trial and have any questions, please contact the trial team on octo-tebemrd@oncology.ox.ac.uk.
Trial Design
TebeMRD is an unblinded non-randomised, open labelled, safety and efficacy study involving 2 patient cohorts:
- A: Cutaneous melanoma with molecular relapsed disease (MRD)
- B: Uveal melanoma with MRD
Approximately 850 patients (600 cutaneous melanoma, 250 uveal melanoma) will be enrolled from 50 centres to screen for HLA-A*0201 status and then followed for up to 24 months for MRD at those same centres. Patients identified with MRD will be invited to be treated with tebentafusp at up to 10 treating centres in the UK. Patients will receive up to six months of tebentafusp, administered weekly IV, and then followed-up for one year for molecular and clinical relapse.
Contact Us:
If you would like more information regarding the trial or have any questions, please contact the trial team:
TebeMRD Trial Team
Email: octo-tebemrd@oncology.ox.ac.uk
Address: Oncology Clinical Trials Office (OCTO). Department of Oncology, The University of Oxford, Old Road Campus Research Building, Oxford, OX3 7DQ
